Quest Diagnostics Inc (NYSE: DGX) has reported earnings for its third fiscal quarter (ending September 30) of $2.18 versus $2.01 for the same period a year ago — an increase of 8%. However, this result fell short of the consensus estimate of $2.51 by $-0.32. For the latest four quarters through September 30, E.P.S. were $8.64 compared to $7.52 a year ago — an increase of 15%.
Recent Price Action
Quest Diagnostics Inc (NYSE: DGX) stock closed at $184.64 on 10/21/25 after a decline of -3.0%. Moreover, trading volume in this decline was exceptionally high at 334% of normal. The stock has risen 1.0% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
Quest Diagnostics has a current Value Trend Rating of C (Low Neutral). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Quest Diagnostics has a slightly negative Appreciation Score of 40 and a neutral Power Rating of 53, producing the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment